We are live on ! Find out more
ABUS icon

Arbutus Biopharma
ABUS

51 hedge funds and large institutions have $47.6M invested in Arbutus Biopharma in 2020 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 14 increasing their positions, 11 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

24,060% more call options, than puts

Call options by funds: $1.21M | Put options by funds: $5K

79% more capital invested

Capital invested by funds: $26.5M → $47.6M (+$21M)

33% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 9

27% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 11

6% more funds holding

Funds holding: 48 → 51 (+3)

0.25% less ownership

Funds ownership: 38.13% → 37.88% (-0.25%)

Holders
51
Holders Change
+3
Holders Change %
+6.25%
% of All Funds
1.05%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
12
Increased
14
Reduced
11
Closed
9
Calls
$1.21M
Puts
$5K
Net Calls
+$1.2M
Net Calls Change
+$467K

Top Buyers

1
Morgan Stanley
Morgan Stanley
New York
+$2.14M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$1.17M
3
Squarepoint
Squarepoint
New York
+$458K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$335K
5
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
+$286K

Top Sellers

1
Citadel Advisors
Citadel Advisors
Florida
-$1.85M
2
Millennium Management
Millennium Management
New York
-$1.02M
3
HP
Hound Partners
New York
-$580K
4
Goldman Sachs
Goldman Sachs
New York
-$448K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$278K
Name Holding Trade Value Shares
Change 		Change in
Stake
Russell Investments Group
26
Russell Investments Group
United Kingdom
$78K +$70.5K +43,100 New
Mackenzie Financial
27
Mackenzie Financial
Ontario, Canada
$73K – – –
Creative Planning
28
Creative Planning
Kansas
$60K +$53.6K +32,748 New
EMG
29
ETF Managers Group
New Jersey
$39K +$33.6K +20,520 New
ECM
30
ExodusPoint Capital Management
New York
$31K +$5.12K +3,131 +23%
VF
31
Virtu Financial
New York
$31K +$28.1K +17,147 New
ARTA
32
A.R.T. Advisors
New York
$26K +$23.1K +14,140 New
CSS
33
Cubist Systematic Strategies
Connecticut
$23K +$20.6K +12,562 New
TRCT
34
Tower Research Capital (TRC)
New York
$21K -$1.47K -899 -7%
SC
35
Scotia Capital
Ontario, Canada
$21K – – –
WS
36
Wedbush Securities
California
$20K -$52.4K -32,000 -74%
FIA
37
FNY Investment Advisers
New York
$18K – – –
SAM
38
Secure Asset Management
Michigan
$18K – – –
Royal Bank of Canada
39
Royal Bank of Canada
Ontario, Canada
$15K +$9.58K +5,856 +243%
SIAP
40
Sterling Investment Advisors (Pennsylvania)
Pennsylvania
$7K – – –
Citigroup
41
Citigroup
New York
$5K -$164 -100 -3%
Wells Fargo
42
Wells Fargo
California
$5K – – –
HIA
43
Harbor Investment Advisory
Maryland
$2K – – –
CB
44
CNB Bank
Pennsylvania
$2K +$1.71K +1,045 New
FDCDDQ
45
Federation des caisses Desjardins du Quebec
Quebec, Canada
$1.46K – – –
TF
46
TimeScale Financial
Massachusetts
$1K – – –
BNP Paribas Financial Markets
47
BNP Paribas Financial Markets
France
$11 -$105 -64 -91%
HP
48
Hound Partners
New York
– -$580K -574,551 Closed
ACP
49
Acuta Capital Partners
California
– -$273K -269,907 Closed
CS
50
Credit Suisse
Switzerland
– -$219K -216,708 Closed
1
2
3

ABUS Hedge Fund Activity: Q2 2020 in Review

51 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q2 2020, worth a combined $47.6M — up 79% from $26.5M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new ABUS positions and 9 closed out — a net gain of 3 holders — while 14 added to existing stakes and 11 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $2.14M. The largest seller was Citadel Advisors, cutting an estimated $1.85M.

  • 51 institutional investors held Arbutus Biopharma (ABUS) as of Q2 2020, up from 48 in Q1 2020.
  • Funds reported $47.6M of Arbutus Biopharma stock for Q2 2020, up 79% quarter-over-quarter.
  • 12 funds opened new Arbutus Biopharma positions in Q2 2020 and 9 closed out, a net change of +3 holders.
  • The largest Arbutus Biopharma buyer in Q2 2020 was Morgan Stanley, an estimated $2.14M added.
  • The largest Arbutus Biopharma seller in Q2 2020 was Citadel Advisors, an estimated $1.85M sold.

Based on aggregated 13F filings for Q2 2020.